<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243800</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0205</org_study_id>
    <nct_id>NCT02243800</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency</brief_title>
  <acronym>SCORPION</acronym>
  <official_title>Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRINEX Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BP 337 - 3 rue de Gentilly</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>92541 MONTROUGE Cedex FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Vitamin D plays a key role in the regulation of calcium metabolism and bone physiology and
      also presents immunomodulatory effects. In contrast to healthy individuals, macrophages and
      synoviocytes synovium of patients with rheumatoid arthritis (RA) have receptors for vitamin
      D. In vitro, 1,25 Vitamin D inhibits T cell proliferation and cytokine synthesis and
      decreases pro-inflammatory process. There is an inverse relationship, at least in some
      epidemiological studies, between the circulating levels of 25OH vitamin D and the occurrence
      and / or activity of RA. The hypothesis of our study is that natural vitamin D
      supplementation in patients with RA and a vitamin D deficiency (vitamin D &lt;30 ng / mL)
      improves functional disability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, multicenter (13 rheumatology units) randomized, double-blinded
      study against placebo, lasting 24 weeks. The main objective is to demonstrate that treatment
      with cholecalciferol improves functional disability (HAQ) in patients with RA not in
      remission (DAS28 VS&gt; 2.6 and the investigator does not think to change the treatment in the 3
      months after enrolment) and vitamin D deficiency (vitamin D &lt;30 ng / ml). Secondary
      objectives will be to examine whether there is a decrease in disease activity (tender joint
      count, swollen joint count, VAS, EVA activity, ESR, CRP, EULAR criteria, ACR), a decrease in
      fatigue (FACIT EVA - fatigue), improved quality of life (SF36, EMIR, PASS, MOS) and the
      impact of RA (RAID).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in functional disability measured by the HAQ between the treated group and the placebo group.</measure>
    <time_frame>at day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The EULAR response criteria</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR response criteria</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of tender joints</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of swollen joints</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVA activity</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters of inflammation</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthenia collected by VAS and FACIT - tiredness</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of RA activity (RAID)</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36, EMIR, MOS, PASS)</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group will receive the study treatment: cholecalciferol One group will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One group will receive the study treatment: cholecalciferol One group will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cholecalciferol versus placebo</intervention_name>
    <arm_group_label>cholecalciferol</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients with RA (ACR 1987) not in remission (DAS28&gt; 2.6) in whom no change in treatment
        is considered by the investigator for at least 3 months, DMARD stable RA for at least 3
        months and lack of infiltration in the last 2 months

        - Serum 25-OH vitamin D &lt;30 ng / ml

        Exclusion Criteria:

          -  Arthritis resulting in class IV functional disability (according to the ACR criteria)

          -  Hypercalcemia (serum calcium&gt; 2.6 mmol/L) and/or known hypercalciuria (calcium
             excretion&gt; 4 mg / kg / day), history of renal colic, thiazideic therapy.

          -  Known hypersensitivity to vitamin D

          -  Patient refused to sign the consent form, pregnant or nursing women, patients minor,
             major patients under protection of the Act
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin SOUBRIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2014</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Cholecalciferol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

